直接口服抗凝药与华法林治疗慢性血栓栓塞性肺动脉高压的长期结局:日本前瞻性队列研究
CTEPH AC注册研究为前瞻性全国队列,纳入927例口服抗凝药的慢性血栓栓塞性肺动脉高压患者,其中481例(52%)使用直接口服抗凝药(DOAC)、446例(48%)使用华法林。两组1、2、3年复合患病和死亡结局率相近(P=.52),DOAC组临床相关出血率显著低于华法林组(P=0.036),多变量Cox回归显示DOAC组临床相关出血风险更低(HR 0.35,95%CI 0.13-0.91,P=.032)。
要点
- DOAC组与华法林组1、2、3年复合患病和死亡结局率相近,差异无统计学显著(P=.52)。
- DOAC组1、2、3年临床相关出血率显著低于华法林组(P=0.036)。
- 多变量分析显示DOAC组临床相关出血风险低于华法林组(HR 0.35,95%CI 0.13-0.91)。
核心结论
- 在当前标准治疗下,无论使用何种抗凝药,患病和死亡事件均得到有效预防,而使用DOAC时临床相关出血率低于华法林。
研究设计与样本
- CTEPH AC注册研究为前瞻性全国队列研究,比较DOAC与华法林在慢性血栓栓塞性肺动脉高压中的安全性和有效性。
- 纳入年龄≥20岁、根据标准指南诊断为慢性血栓栓塞性肺动脉高压的患者,包括初治和正在治疗者;排除标准未具体说明。
- 基线口服抗凝药患者927例纳入分析:DOAC组481例(52%),华法林组446例(48%)。
主要发现
- DOAC组与华法林组1、2、3年复合患病和死亡结局率分别为2.6%、3.1%、4.2%与3.0%、4.8%、5.9%,差异无统计学显著(P=.52)。
- DOAC组与华法林组1、2、3年临床相关出血率分别为0.8%、2.4%、2.4%与2.5%、4.8%、6.4%,DOAC组显著低于华法林组(P=0.036)。
- 多变量Cox比例风险回归显示DOAC组临床相关出血风险低于华法林组(HR 0.35,95%CI 0.13-0.91,P=.032)。
关键数值与推荐
- 主要有效性结局为复合患病和死亡结局,包括全因死亡、补救性再灌注治疗、开始肠外肺血管扩张剂治疗、6分钟步行距离恶化及WHO功能分级恶化。
- 安全性结局为临床相关出血,包括大出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) requires lifelong anticoagulation. Long-term outcomes of CTEPH under current anticoagulants are unclear. OBJECTIVES: The CTEPH AC registry is a prospective, nationwide cohort study comparing the safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for CTEPH. PATIENTS/METHODS: Patients with CTEPH, both tre atment-naïve and on treatment, were eligible for the registry. Inclusion criteria were patients aged ≥20 years and those who were diagnosed with CTEPH according to standard guidelines. Exclusion criteria were not specified. The primary efficacy outcome was a composite morbidity, and mortality outcome comprised all-cause death, rescue reperfusion therapy, initiation of parenteral pulmonary vasodilators, and worsened 6-minute walk distance and WHO functional class. The safety outcome was clinically relevant bleeding, including major bleeding. RESULTS: Nine hundred twenty-seven patients on oral anticoagulants at baseline were analyzed: 481 (52%) used DOACs and 446 (48%) used warfarin. The 1-, 2-, and 3-year rates of composite morbidity and mortality outcome were comparable between the DOAC and warfarin groups (2.6%, 3.1%, and 4.2% vs 3.0%, 4.8%, and 5.9%, respectively; P = .52). The 1-, 2-, and 3-year rates of clinically relevant bleeding were significantly lower in DOACs than in the warfarin group (0.8%, 2.4%, and 2.4% vs 2.5%, 4.8%, and 6.4%, respectively; P = 0.036). Multivariable Cox proportional-hazards regression models revealed lower risk of clinically relevant bleeding in the DOAC group than the warfarin group (hazard ratio: 0.35; 95% CI: 0.13-0.91; P = .032). CONCLUSION: This registry demonstrated that under current standard of care, morbidity and mortality events were effectively prevented regardless of anticoagulants, while the clinically relevant bleeding rate was lower when using DOACs compared with warfarin.
引用
- Hosokawa K, Abe K, Funakoshi K, et al. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. J Thromb Haemost. 2023. PMID: 37044277. doi:10.1016/j.jtha.2023.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。